Join Growin Stock Community!

Daré bioscience, inc.DARE.US Overview

US StockHealthcare
(No presentation for DARE)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

DARE AI Insights

DARE Overall Performance

DARE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

DARE Recent Performance

-2.17%

Daré bioscience, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

DARE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

DARE Key Information

DARE Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

DARE Profile

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Price of DARE

DARE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

DARE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.83
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
751.51
PB Ratio
8.45
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-44.71%
Net Margin
30568.80%
Revenue Growth (YoY)
-103.04%
Profit Growth (YoY)
-98.60%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.83
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
751.51
PB Ratio
8.45
Price-to-FCF
-
Gross Margin
-44.71%
Net Margin
30568.80%
Revenue Growth (YoY)
-103.04%
Profit Growth (YoY)
-98.60%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is DARE's latest earnings report released?

    The most recent financial report for Daré bioscience, inc. (DARE) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DARE's short-term business performance and financial health. For the latest updates on DARE's earnings releases, visit this page regularly.

  • What is the operating profit of DARE?

    According to the latest financial report, Daré bioscience, inc. (DARE) reported an Operating Profit of -3.67M with an Operating Margin of -162,340.76% this period, representing a growth of 21.56% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is DARE's revenue growth?

    In the latest financial report, Daré bioscience, inc. (DARE) announced revenue of 2.26K, with a Year-Over-Year growth rate of -94.57%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does DARE have?

    As of the end of the reporting period, Daré bioscience, inc. (DARE) had total debt of 2.93M, with a debt ratio of 0.1. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does DARE have?

    At the end of the period, Daré bioscience, inc. (DARE) held Total Cash and Cash Equivalents of 23.08M, accounting for 0.75 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does DARE go with three margins increasing?

    In the latest report, Daré bioscience, inc. (DARE) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -162,340.76%%, and net margin of -157,505.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess DARE's profit trajectory and future growth potential.

  • Is DARE's EPS continuing to grow?

    According to the past four quarterly reports, Daré bioscience, inc. (DARE)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.28. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of DARE?

    Daré bioscience, inc. (DARE)'s Free Cash Flow (FCF) for the period is -616.84K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 89.07% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of DARE?

    The latest valuation data shows Daré bioscience, inc. (DARE) has a Price-To-Earnings (PE) ratio of -1.55 and a Price/Earnings-To-Growth (PEG) ratio of 0.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.